{"title":"SIGN updates its guideline on the management of migraine","authors":"S. Chaplin","doi":"10.1002/psb.2048","DOIUrl":null,"url":null,"abstract":"The Scottish Intercollegiate Guidelines Network (SIGN) has recently updated its guideline on the pharmacological management of migraine (SIGN 155) to include new information on the use of anti‐CGRP monoclonal antibodies. This article provides a round‐up of the main changes to the guidance.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"48 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2048","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The Scottish Intercollegiate Guidelines Network (SIGN) has recently updated its guideline on the pharmacological management of migraine (SIGN 155) to include new information on the use of anti‐CGRP monoclonal antibodies. This article provides a round‐up of the main changes to the guidance.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
